Norvium Bioscience Company Profile
✉ Email this page to a colleague
What is the competitive landscape for NORVIUM BIOSCIENCE
NORVIUM BIOSCIENCE has four approved drugs.
Summary for Norvium Bioscience
| US Patents: | 0 |
| Tradenames: | 4 |
| Ingredients: | 4 |
| NDAs: | 4 |
Drugs and US Patents for Norvium Bioscience
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Norvium Bioscience | TADALAFIL | tadalafil | TABLET;ORAL | 206957-001 | Apr 29, 2019 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Norvium Bioscience | SUMATRIPTAN SUCCINATE | sumatriptan succinate | INJECTABLE;SUBCUTANEOUS | 203322-001 | Apr 14, 2014 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Norvium Bioscience | TRIAMCINOLONE ACETONIDE | triamcinolone acetonide | CREAM;TOPICAL | 011601-003 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Norvium Bioscience
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Norvium Bioscience | EVOCLIN | clindamycin phosphate | AEROSOL, FOAM;TOPICAL | 050801-001 | Oct 22, 2004 | 7,141,237 | ⤷ Start Trial |
| Norvium Bioscience | EVOCLIN | clindamycin phosphate | AEROSOL, FOAM;TOPICAL | 050801-001 | Oct 22, 2004 | 7,374,747 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
